Clinical Trial Update: Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene [Phase 2]

View source ↗

Summary

Capecitabine was evaluated as a second-line therapy for stage IV pancreatic cancer in a Phase 2 trial, which has completed. The trial focused on patients with t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED